Citius Pharmaceuticals, Inc.

Citius Pharmaceuticals, Inc. company information, Employees & Contact Information

Citius Pharmaceuticals, Inc. (Nasdaq: CTXR) is a late-stage biopharmaceutical company focused on the development and commercialization of first-in-class critical care products, with a pipeline of anti-infectives in adjunct cancer care, stem cell therapy and unique prescription products.

Company Details

Employees
20
Founded
-
Address
11 Commerce Dr,
Phone
(908)967-6677
Email
in****@****rma.com
Industry
Pharmaceutical Manufacturing
NAICS
Pharmaceutical and Medicine Manufacturing
Medicinal and Botanical Manufacturing
Pharmaceutical Preparation Manufacturing
In-Vitro Diagnostic Substance Manufacturing
Biological Product (except Diagnostic) Manufacturing
HQ
Cranford, New Jersey
Looking for a particular Citius Pharmaceuticals, Inc. employee's phone or email?

Citius Pharmaceuticals, Inc. Questions

News

Citius Pharmaceuticals Announces the Closing of Registered Direct Offering of $6.0 Million Priced At-The-Market Under Nasdaq Rules - Sahm

Citius Pharmaceuticals Announces the Closing of Registered Direct Offering of $6.0 Million Priced At-The-Market Under Nasdaq Rules Sahm

Citius Pharmaceuticals and Citius Oncology to Participate in Upcoming October 2025 Conferences - StreetInsider

Citius Pharmaceuticals and Citius Oncology to Participate in Upcoming October 2025 Conferences StreetInsider

Citius Oncology Announces Closing of $9.0 Million Registered Direct Offering and Concurrent Private Placement - PR Newswire

Citius Oncology Announces Closing of $9.0 Million Registered Direct Offering and Concurrent Private Placement PR Newswire

Citius Pharma Advances Mino-Lok After Successful FDA Meeting, Phase 3 Trial Results - Stock Titan

Citius Pharma Advances Mino-Lok After Successful FDA Meeting, Phase 3 Trial Results Stock Titan

Citius Pharmaceuticals, Inc. Announces 1-for-25 Reverse Stock Split - Yahoo Finance

Citius Pharmaceuticals, Inc. Announces 1-for-25 Reverse Stock Split Yahoo Finance

Citius Pharmaceuticals, Inc. Reports Fiscal Third Quarter 2025 Financial Results and Provides Business Update - PR Newswire

Citius Pharmaceuticals, Inc. Reports Fiscal Third Quarter 2025 Financial Results and Provides Business Update PR Newswire

Citius Pharmaceuticals (NASDAQ: CTXR) announces $6.0M registered direct for 3.97M shares - Stock Titan

Citius Pharmaceuticals (NASDAQ: CTXR) announces $6.0M registered direct for 3.97M shares Stock Titan

Citius Oncology Enters into Distribution Services Agreement with Cardinal Health - Yahoo Finance

Citius Oncology Enters into Distribution Services Agreement with Cardinal Health Yahoo Finance

Citius Secures $21.5M Funding as Cancer Drug LYMPHIR Nears Q4 2025 Commercial Launch - Stock Titan

Citius Secures $21.5M Funding as Cancer Drug LYMPHIR Nears Q4 2025 Commercial Launch Stock Titan

Citius Pharmaceuticals, Inc. Reports Fiscal Second Quarter 2025 Financial Results and Provides Business Update - Yahoo Finance

Citius Pharmaceuticals, Inc. Reports Fiscal Second Quarter 2025 Financial Results and Provides Business Update Yahoo Finance

Citius Pharmaceuticals Completes Merger of Subsidiary with TenX Keane to form Citius Oncology, Inc. - PR Newswire

Citius Pharmaceuticals Completes Merger of Subsidiary with TenX Keane to form Citius Oncology, Inc. PR Newswire

Citius Pharmaceuticals to Present at the Jefferies Global Healthcare Conference - Yahoo Finance

Citius Pharmaceuticals to Present at the Jefferies Global Healthcare Conference Yahoo Finance

Citius Pharmaceuticals Announces TenX Keane Shareholder Approval of Merger with Citius Oncology, Inc. - PR Newswire

Citius Pharmaceuticals Announces TenX Keane Shareholder Approval of Merger with Citius Oncology, Inc. PR Newswire

Citius Pharmaceuticals Achieves Primary and Secondary Endpoints in Phase 3 Trial of Mino-Lok Antibiotic Lock Solution - PR Newswire

Citius Pharmaceuticals Achieves Primary and Secondary Endpoints in Phase 3 Trial of Mino-Lok Antibiotic Lock Solution PR Newswire

Citius Pharmaceuticals Executes Definitive Agreement to Merge Wholly Owned Subsidiary with TenX Keane Acquisition to Form Publicly Listed Citius Oncology, Inc. - PR Newswire

Citius Pharmaceuticals Executes Definitive Agreement to Merge Wholly Owned Subsidiary with TenX Keane Acquisition to Form Publicly Listed Citius Oncology, Inc. PR Newswire

Top Citius Pharmaceuticals, Inc. Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant